Order results by:
| Issue | Title | |
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... . The hypothesis about CYP и SULT1A enzymes influence on apixaban metabolism was examined. To date, numerous SNVs ..." | ||
| Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..." | ||
| Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
| D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
| "... to apixaban use in clinical practice: examination before apixaban administration, clinical situation when ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... the efficacy and safety of the use of direct oral anticoagulants (DOACs) in clinical practice. Data on drug ..." | ||
| Vol 11, No 6 (2015) | Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events | Abstract similar documents |
| O. V. Shatalova | ||
| "... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... patients; 2) one of the studies of real clinical practice showed that only therapy with rivaroxaban (out ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... ) contained data on the participation of frail patients; 2) one of the studies of real clinical practice ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... with non-valvular AF rivaroxaban use is more effective, than the use of apixaban, from the clinical ..." | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... The review actualizes the need to validate data obtained in randomized clinical trials (RCT ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... The purpose of this review is to analyze the results of randomized clinical trials, meta-analyses ..." | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... Large randomized clinical trials (RCTs) in patients with non-valvular atrial fibrillation (AF ..." | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... Aim. The aim of our study was to investigate the influence of polymorphic markers of CYP3A4*22 CYP ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... rare side effects. This article describes a clinical case of rivaroxaban-associated drug-induced liver ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| "... ) became very important in clinical practice. The article presents a contemporary view of the advantages ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| "... in accordance with clinical guidelines. Material and methods. Control Of Anticoagulation Therapy in Atrial ..." | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... of the additional costs of apixaban, that help to achieve significant advantages from a clinical point of view ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..." | ||
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... of bleeding. The data of subanalysis of the ARISTOTEL randomized clinical trial, indicating a high profile ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| "... completed randomized clinical trials evaluating the effects of direct oral anticoagulants are presented ..." | ||
| Vol 12, No 3 (2016) | THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE | Abstract PDF (Eng) similar documents |
| A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko | ||
| "... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... comparing clinical effectiveness and safety of apixaban with warfarin (ARISTOTLE) and acetylsalicylic acid ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| "... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..." | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... The article presents a clinical observation of the left atrial appendage thrombosis in a 51-year ..." | ||
| Vol 16, No 3 (2020) | Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue | Abstract similar documents |
| O. D. Ostroumova, I. V. Goloborodova | ||
| Vol 10, No 3 (2014) | EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION | Abstract similar documents |
| "... European Medicines Agency approved apixaban use in cardioversion. ..." | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| "... indications and to analyze the published clinical cases of drug induced liver injury (DILI) development ..." | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... , obtained both from randomized clinical trials and from daily clinical practice. In the ROCKET AF trail ..." | ||
| Vol 15, No 4 (2019) | Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen | Abstract similar documents |
| A. I. Kochetkov, O. D. Ostroumova | ||
| "... be prescribed, in these clinical conditions the effectiveness and safety of apixaban is also proven ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| "... to improve the tactics of using direct oral anticoagulants (DOACs) therapy. Clinical situations in which ..." | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... a DOAC in elderly patients with AF or VTE, one should primarily focus on current clinical guidelines ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... in a nonrandomized observational study of new oral anticoagulants (NOAC) in real clinical practice. A history ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| "... to clinical guidelines vitamin K antagonists (VKAs) should be used as treatment of choice for thrombus ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| "... Представлены данные литературы об актуальности проблемы тромбоэмболических осложнений при ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| "... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
| Company Pfizer | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... The considered clinical case of combination of multifocal atherosclerotic vascular lesion ..." | ||
| Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
| "... The clinical significance of CYP2C19 genetic polymorphism, associated with the violation ..." | ||
| Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
| S. J. Martsevich | ||
| "... The ACC/AHA clopidogrel clinical alert about the possibility of ineffective treatment ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
| Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
| A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
| "... Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization ..." | ||
| Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
| A. V. Rudakova | ||
| "... incidence in patients aged 60-65years, was developed based on the results of such clinical trials as ADVANCE ..." | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... among anticoagulants (36.7%). About a third of respondents were prescribed apixaban by a doctor (30 ..." | ||
| Vol 16, No 4 (2020) | The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... is inferior to apixaban in its ability to prevent ischemic stroke and systemic embolism and is more likely ..." | ||
| Vol 18, No 4 (2022) | The effect of rs776746 polymorphism in the CYP3A5 gene on heart rate when using bisoprolol in patients with acute coronary syndrome | Abstract similar documents |
| V. A. Shumkov, K. A. Zagorodnikova, S. A. Boldueva, A. A. Murzina | ||
| "... protein CYP3A5, coupled with an increased metabolic rate. Patients did not differ in clinical ..." | ||
| Vol 11, No 5 (2015) | Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism | Abstract similar documents |
| A. V. Rudakova | ||
| "... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..." | ||
| Vol 14, No 4 (2018) | Role of Single Nucleotide Polymorphism of СУР17А Gene in the Development of Stroke | Abstract similar documents |
| S. Yu. Nikulina, V. A. Shulman, A. A. Chernova, D. A. Nikulin, A. A. Semenchukov, O. V. Marilovceva, S. S. Tret'jakova, I. I. Lebedeva, V. N. Maksimov | ||
| "... CYP17A1 is one of the many genes that can participate in the formation of predisposition ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| "... The clinical significance of the patient genetic characteristics in the individual pharmacological ..." | ||
| Vol 3, No 2 (2007) | VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY | Abstract similar documents |
| D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes | ||
| "... of polymorphisms of genes of their biotransformation (CYP2C9) and molecule-targets (VKORC1). This created basis ..." | ||
| Vol 17, No 1 (2021) | Pharmacogenetics as a Way for Personalizing Diuretic Therapy: Focus on Torasemide | Abstract similar documents |
| N. M. Gafurova, E. V. Shikh, O. D. Ostroumova | ||
| "... are used in almost 80% of cases. Currently, there are not enough clinical studies, which comparative ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... , rivaroxaban, apixaban, and edoxaban) over the vitamin K antagonist warfarin in elderly patients with geriatric ..." | ||
| Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
| "... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..." | ||
| Vol 15, No 3 (2019) | Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population | Abstract similar documents |
| K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko, D. A. Sychev | ||
| "... of evidence of clinical validity and clinical utility of other pharmacogenetic markers (CES1, CYP2D6*4, etc ..." | ||
| Vol 11, No 4 (2015) | SLEEP DURATION: MODERN VIEW OF THE PROBLEM FROM THE STANDPOINT OF A CARDIOLOGIST | Abstract similar documents |
| O. M. Drapkina, R. N. Shepel' | ||
| "... , including cardiovascular diseases is known and proven. In addition, the results of many clinical studies ..." | ||
| Vol 16, No 2 (2020) | The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment | Abstract similar documents |
| К. V. Lobastov, I. V. Schastlivtsev | ||
| "... patients have been published: SELECT-D (rivaroxaban), HOKUSAI-VTE Cancer (edoxaban), ADAM VTE (apixaban ..." | ||
| Vol 10, No 2 (2014) | HYPERPHAGIA REACTIONS WITHIN EATING DISORDERS. CLINICAL FEATURES AND THERAPY | Abstract similar documents |
| O. A. Gladyshev | ||
| "... Aim. To evaluate clinical features of hyperphagia reactions, their significance in attraction ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
| Vol 15, No 3 (2019) | Medication Adherence: does Patient Participation in Randomized Clinical Trials Affect on it? | Abstract similar documents |
| N. O. Vasyukova, Yu. V. Lukina, N. P. Kutishenko, S. Yu. Martsevich, O. I. Zvonareva | ||
| "... ., the absence of a “gold standard” for assessing adherence in clinical practice makes it difficult to predict ..." | ||
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| "... of clopidogrel play an important role in the resistance development. Allel variants of the gene cytochrome CYP2C ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 17, No 4 (2021) | Approaches to Assessing the Quality of Observational Studies of Clinical Practice Based on the Big Data Analysis | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... studies in real clinical practice and determining their place in the hierarchy of evidence-based ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... Aim. To analyze published clinical trials to evaluate the safety and effectiveness of direct oral ..." | ||
| Vol 7, No 2 (2011) | EVALUATION OF CARDIOVASCULAR RISK FACTORS PREVALENCE AND EFFICACY OF THEIR CORRECTION IN PHYSICIANS. ESTIMATION OF PHYSICIANS’ EXPERTISE IN UP-TO-DATE CLINICAL GUIDELINES. RESULTS OF THE “PHYSICIAN’S HEALTH AND EDUCATION” STUDY | Abstract similar documents |
| L. Y. Drozdova, S Y. Martsevich, V. P. Voronina | ||
| "... their own cardiovascular risk, and to simultaneously assess their expertise in up-to-date clinical ..." | ||
| Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
| "... Aim. Carriership of CYP2C19*2 allelic variant and reduced CYP3A4 activity can affect the formation ..." | ||
| Vol 17, No 4 (2021) | Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery | Abstract similar documents |
| T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Zh. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. A. Grishina, D. A. Sychev | ||
| "... therapy in patients with CYP2C9*2 (430C>T) rs179985 and CYP2C9*3 (1075A>C) rs1057910 gene polymorphisms ..." | ||
| Vol 10, No 4 (2014) | OPTIMAL PREVENTION OF HOSPITAL VENOUS THROMBOEMBOLISM WITH THE HELP OF MEDICAL INFORMATION SYSTEM | Abstract similar documents |
| G. I. Nazarenko, S. A. Payushk, V. A. Otdelenov, E. B. Kleymenova, L. P. Yashina, D. A. Sychev | ||
| "... of clinical guidelines for the prevention of venous thromboembolic complications there is a gap between ..." | ||
| Vol 15, No 5 (2019) | Findings Released from NAXOS Analysis. Pfizer Company Press Release | Abstract similar documents |
| article Editorial | ||
| "... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..." | ||
| Vol 18, No 2 (2022) | Postural Orthostatic Tachycardia Syndrome as a Manifestation of Post-COVID-19 Syndrome | Abstract similar documents |
| E. L. Trisvetova | ||
| "... расстройства функции многих органов и систем организма, обусловила появление новых проблем, далеких от ..." | ||
| Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
| "... Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet ..." | ||
| Vol 13, No 3 (2017) | THE PREVALENCE AND CLINICAL SIGNIFICANCE OF CARDIAC ARRHYTHMIAS | Abstract similar documents |
| E. V. Zatonskaya, G. V. Matyushin, N. G. Gogolashvili | ||
| "... urgent problems of modern cardiology. A wide spectrum of clinical manifestations of cardiac rhythm ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... . Other clinical characteristics and laboratory indices, including CYP2C19*2 carriage, showed ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..." | ||
| Vol 12, No 5 (2016) | Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms | Abstract PDF (Eng) similar documents |
| Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev | ||
| "... Aim. To evaluate treatment adherence and prevalence of CYP2C9 and VKORC1 gene mutations ..." | ||
| Vol 13, No 4 (2017) | GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS | Abstract similar documents |
| M. A. Vorobyeva, M. M. Azova, O. O. Gigani, I. V. Garmash, S. V. Villevalde, Zh. D. Kobalava | ||
| "... , 62.1% of men) were included into the study. Polymorphism Phe189Ser of the CYP3A4 (gene encoding ..." | ||
| Vol 14, No 1 (2018) | NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Ju. P. Skirdenko, N. A. Nikolayev | ||
| "... , polymorphism of genes CYP2C9 and VKORC1 and the structure of food preferences. Results. Persons ..." | ||
| Vol 18, No 3 (2022) | Historical Aspects of the Use of Antiarrhythmic Drugs in Clinical Practice | Abstract similar documents |
| V. L. Doshchitsin, A. I. Tarzimanova | ||
| "... the second half of the 20th century, when new antiarrhythmic drugs began to be used in clinical practice ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... .6%) started or continued taking rivaroxaban 20 mg 1 time/day and 3 (4.4%) started or continued taking apixaban ..." | ||
| Vol 5, No 2 (2009) | REASONS FOR Β-ADRENOBLOCKER USE IN ARTERIAL HYPERTENSION: ONE MORE TIME ABOUT PRO AND CONTRA | Abstract similar documents |
| V. I. Makolkin | ||
| "... Results of clinical trials devoted to β-adrenoblocker use in arterial hypertension (HT ..." | ||
| Vol 6, No 2 (2010) | EVALUATION BY PRACTICING DOCTORS OF THE MODERN PHARMACOTHERAPY POSSIBILITIES IN PATIENTS WITH ISCHEMIC HEART DISEASE. RESULTS OF DOCTOR INTERVIEW IN MOSCOW AND VORONEZH | Abstract similar documents |
| S. Yu. Martsevich, L. Yu. Drozdova, Yu. V. Lukina, N. V. Sinyagina, T. G. Kheliya | ||
| "... of modern clinical guidelines on IHD therapy. On the other hand they gave understanding why doctors ..." | ||
| Vol 6, No 4 (2010) | RUSSIAN CLINICAL TRAILS IN CARDIOLOGY. YESTERDAY, TODAY AND TOMORROW | Abstract similar documents |
| S. A. Shalnova, S. Y. Martsevich | ||
| "... The organization of randomized clinical trials (RCTs) in accordance to the principles of Good ..." | ||
| Vol 10, No 5 (2014) | NEWS FROM THE ANNUAL CONGRESS OF EUROPEAN SOCIETY OF CARDIOLOGY (BARCELONA 2014): REALIZED AND UNREALIZED EXPECTATIONS | Abstract similar documents |
| S. Y. Martsevich, N. P. Kutishenko | ||
| "... of recent controlled clinical trials, new clinical recommendations and registers data that were presented ..." | ||
| Vol 14, No 4 (2018) | New Clinical Aspects of Eplerenone Use in Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy, N. G. Bendeliani, M. V. Golshmid, I. M. Kuzmina | ||
| "... fraction and insufficiently frequent their use in clinical practice for the treatment of these patients ..." | ||
| Vol 14, No 5 (2018) | News of the Annual Congress of the European Society of Cardiology in Munich: Research to Help Practical Medicine | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... clinical trials (RCTs) are reviewed. The RCTs presented at the congress were mainly devoted not to new ..." | ||
| Vol 12, No 1 (2016) | Features of pharmacotherapy in the elderly patients. Introduction to the problem | Abstract similar documents |
| E. A. Ushkalova, O. N. Tkacheva, N. K. Runikhina, N. A. Chukhareva, A. Yu. Bevz | ||
| Vol 7, No 2 (2011) | LIPRIMAR®. FIFTEEN YEARS OF EVIDENCE | Abstract similar documents |
| A. V. Susekov, N. V. Khokhlova | ||
| "... of atorvastatin is demonstrated in according to comparative studies. Results of clinical studies on atorvastatin ..." | ||
| Vol 5, No 1 (2009) | EMOTIONAL BURNOUT SYNDROME: EFFECT ON CLINICAL INERTIA AND MEDICAL PRACTICE STEREOTYPES | Abstract PDF (Eng) similar documents |
| R. A. Khokhlov, E. V. Minakov, G. I. Furmenko, N. M. Akhmedzhanov | ||
| "... practice stereotypes and on clinical inertia. Material and Methods. The anonymous single-stage poll ..." | ||
| 1 - 100 of 980 Items | 1 2 3 4 5 6 7 8 9 10 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
